| This week's sponsor is Pfizer. | | | |
Top Stories Thursday, December 1, 2016 CAR-T biotech Bluebird Bio has released topline data for its experimental med bb2121 in heavily pre-treated multiple myeloma in a small, positive study that has not shown the serious side effects and deaths associated with Juno’s recent test of a similar treatment. Thursday, December 1, 2016 AstraZeneca has penned a pact to develop bicyclic peptides with Bicycle Therapeutics. The value of the upfront payment, R&D funding and milestones could swell to $1 billion in the unlikely event all programs in the multi-target respiratory, cardiovascular and metabolic disease collaboration come to market. Thursday, December 1, 2016 A litmus test of President-elect Donald Trump's plans for the FDA will come when the agency's commissioner, Dr. Robert Califf, hands in his resignation letter in the coming weeks. Thursday, December 1, 2016 Facebook and Napster billionaire Sean Parker has seen his Institute for Cancer Immunotherapy join forces with the Cancer Research Institute (CRI) to work on boosting personalized medicine. Wednesday, November 30, 2016 The executive shake-up following the formation of QuintilesIMS last month continues, with the appointment of CRO veteran Richard Staub as president of the firm's R&D solutions division. Wednesday, November 30, 2016 Australian scientists have found a potential new angle for diabetes treatment in the unlikeliest of places: the venom of the platypus and the echidna. These animals produce a stable version of the hormone glucagon-like peptide-1, which could lead to a longer-lasting version of the hormone for people with Type 2 diabetes. Thursday, December 1, 2016 IBM is launching the latest addition to the Watson family: Watson for Drug Discovery, which will use cognitive computing to help researchers zero in on new drug targets. First up is a collaboration with Pfizer, which will use the tech to boost its immuno-oncology research. | | | New data from a midstage test of Amgen and Cytokinetics' omecamtiv mecarbil showed it "significantly improved" cardiac function in certain patients with heart failure. Release Heat Biologics was down nearly 60% premarket on news that its experimental cancer med HS-410 failed to hit its primary endpoint. Statement Arsanis has seen the FDA attach its fast track tag to ASN100 for the prevention of Staphylococcus aureus pneumonia in certain very ill patients. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA DeviceTalks December 12, 2016 | Newport Beach, CA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd | 